unnamed.jpg

Arvind in the Press

Arvind was honored with the F50 Global Award for Impact in HealthTech Innovation. He is a frequent speaker at TechCrunch Disrupt, Slush, TedX and Future FoodTech. His work has been profiled in global media outlets such as Bloomberg News, Forbes, The Guardian UK, Neo.life, Nikkei News, Rotman, The Times of India, and CGTN in China. Arvind is a guest lecturer at UCSF, MIT and Harvard.

Want to interview Arvind?

If you are interested in interviewing Arvind on the future of human and planetary health, please leave your name, email and your message.

 

Featured
IndieBio’s Arvind Gupta Joins Mayfield, Will Lead New Alliance Using Capitalism And Biology To Do Good In The World
IndieBio’s Arvind Gupta Joins Mayfield, Will Lead New Alliance Using Capitalism And Biology To Do Good In The World

Global venture capital firm Mayfield announced today that IndieBio’s Arvind Gupta will join its firm to expand its engineering biology initiatives. In addition, Mayfield has partnered with SOSV, the parent firm of IndieBio, to found the Genesis Consortium, an alliance of funds and corporations to promote human and planetary evolution.

Gupta will remain a Venture Advisor at IndieBio, while Po Bronson will become its new Managing Director.

How I Raised My First Dollar with Arvind Gupta
How I Raised My First Dollar with Arvind Gupta

Arvind Gupta is a General Partner at SOSV and the founder and managing director of IndieBio. He spends his days empowering scientists to bring groundbreaking biotech innovations to life through a unique, insensitive accelerator. Aside from his work as a VC, he’s also a designer, a father, a husband, and a lifelong athlete. He’s inspired to create change that will impact the problems facing our planet and lives by a simple mantra which he also imparts on his children: create more than you consume. Arvind shares how he landed in biotech, what drives him as a venture capitalist, and how he raised his first fund.

The Genesis Consortium will elevate their work to transform human and planetary health with engineering biology
The Genesis Consortium will elevate their work to transform human and planetary health with engineering biology

Global venture capital firm Mayfield announced today that IndieBio’s Arvind Gupta will join its firm to expand its engineering biology initiatives. In addition, Mayfield has partnered with SOSV, the parent firm of IndieBio, to found the Genesis Consortium, an alliance of funds and corporations to promote human and planetary evolution.

Gupta will remain a Venture Advisor at IndieBio, while Po Bronson will become its new Managing Director.

Blog Post Title Four
Blog Post Title Four

It all begins with an idea.

Featured Outlets

PR Logos.002.jpeg

IndieBio’s Arvind Gupta Joins Mayfield, Will Lead New Alliance Using Capitalism And Biology To Do Good In The World

Global venture capital firm Mayfield announced today that IndieBio’s Arvind Gupta will join its firm to expand its engineering biology initiatives. In addition, Mayfield has partnered with SOSV, the parent firm of IndieBio, to found the Genesis Consortium, an alliance of funds and corporations to promote human and planetary evolution. 

Gupta will remain a Venture Advisor at IndieBio, while Po Bronson will become its new Managing Director.

Leaving the $3.2 billion portfolio he helped build at IndieBio, Arvind Gupta joins Mayfield to create the Genesis Consortium

Arvind Gupta, the founder and head of IndieBio, is leaving the accelerator whose portfolio he helped build into a $3.2 billion life sciences powerhouse, to join the venture capital fund Mayfield.

The move is a signal both of Mayfield’s increasing commitment to invest in a thesis around human and planetary health, and of the growing importance of bio-engineering in the world of emerging technologies.

Arvind Gupta’s Jiu Jitsu makes biotech move at Silicon Valley speed

He built a powerful system for launching scientific ideas into startups. Can he do it again?

Arvind Gupta seems an unlikely person to lead the renaissance in synthetic biology. Though he studied genetics at UC Santa Barbara, he did not continue that path, and in the two decades before starting the life sciences accelerator IndieBio in San Francisco, he didn’t invent a drug or bring one to market, and he wasn’t a partner at a venture fund investing in biotech.